Kyowa Kirin EMEA, a subsidiary of the global specialty pharmaceutical company Kyowa Kirin, has announced a significant milestone with the European Commission (EC) granting expanded approval for Crysvita (burosumab) to treat X-linked hypophosphataemia (XLH) in infants aged one month to one year across the European Union (EU) and European Economic Area (EEA). This pivotal regulatory decision paves the way for healthcare professionals to intervene earlier in the course of this rare and debilitating genetic disorder, offering a new horizon of hope for the youngest patients and their families.
A Landmark Regulatory Decision for Pediatric XLH
The EC’s approval represents a critical advancement in the management of XLH, particularly for its most vulnerable patient population. Previously, treatment options for infants in this age bracket were limited, often focusing on symptomatic management rather than addressing the underlying pathological mechanisms. With this expanded indication, burosumab becomes available to infants from as young as one month, allowing for earlier therapeutic intervention aimed at preventing or mitigating the severe skeletal and developmental complications associated with XLH. The decision underscores a growing understanding of rare diseases and the commitment of regulatory bodies to facilitate access to innovative therapies for underserved patient groups.
X-linked hypophosphataemia is a rare, lifelong genetic condition that affects approximately 1 in 20,000 to 1 in 25,000 live births globally, though precise prevalence figures can vary by region. It is characterized by renal phosphate wasting, which leads to chronically low phosphate levels in the blood (hypophosphataemia). Phosphate is an essential mineral crucial for bone and teeth formation, energy metabolism, and cell function. In XLH, this deficiency results in impaired bone mineralization, leading to a range of severe clinical manifestations that typically emerge in infancy or early childhood.
The Path to Approval: A Chronology of Regulatory Milestones
The EC’s final approval did not come in isolation but was the culmination of a rigorous evaluation process. This announcement follows a positive recommendation issued in April 2026 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP, responsible for preparing EMA opinions on human medicines, meticulously reviews scientific data on the quality, safety, and efficacy of new drugs or new indications for existing drugs. Its positive opinion is a crucial precursor to EC approval, signaling that the committee believes the benefits of the medicine outweigh its risks for the proposed indication.
This European regulatory success also aligns with other significant global developments for burosumab. Just a month prior, in May 2026, Kyowa Kirin received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing information for Crysvita, introducing a new, more flexible option for adults with XLH. These concurrent approvals highlight the global efforts to optimize and expand access to burosumab for the XLH community across all age groups. Burosumab had previously received approval for older pediatric and adult XLH populations in both Europe and the United States, marking a transformative shift from traditional treatments. The latest EC approval specifically addresses the critical gap in early infant care, emphasizing the importance of initiating therapy during the earliest stages of the disease to potentially alter its long-term trajectory.
Understanding X-Linked Hypophosphataemia (XLH): A Devastating Rare Disease
XLH is primarily caused by mutations in the PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) gene, located on the X chromosome. This genetic defect leads to an overproduction and elevated activity of fibroblast growth factor 23 (FGF23), a hormone that plays a central role in phosphate homeostasis. Normally, FGF23 helps regulate phosphate levels by increasing its excretion by the kidneys and reducing the production of active vitamin D. In XLH, excessive FGF23 causes excessive phosphate loss in the urine and impairs the kidneys’ ability to convert vitamin D into its active form, calcitriol. Both mechanisms contribute to chronic hypophosphataemia and lead to severe consequences.
In infants and young children, XLH typically manifests as rickets, characterized by soft, weak bones that can lead to bowing of the legs, short stature, and other skeletal deformities. Other common symptoms include bone pain, muscle weakness, dental abscesses, craniosynostosis (premature fusion of skull bones), and impaired growth. These complications can significantly impact a child’s mobility, quality of life, and overall development. Without effective treatment, the progression of skeletal deformities can necessitate multiple corrective surgeries and lead to lifelong disability. Traditional treatments for XLH have involved multiple daily doses of oral phosphate supplements and active vitamin D analogs. While these therapies can help raise phosphate levels, they often come with challenges such as gastrointestinal side effects, the need for frequent dosing, and the inability to fully normalize phosphate levels or completely prevent the progression of skeletal deformities. Moreover, high doses of phosphate and active vitamin D can lead to complications such as nephrocalcinosis (calcium deposits in the kidneys) and hypercalcemia.
Crysvita (Burosumab): A Targeted Therapeutic Approach
Burosumab, marketed as Crysvita, represents a paradigm shift in the treatment of XLH. It is a recombinant human monoclonal antibody that directly targets and binds to FGF23. By inhibiting the excessive activity of FGF23, burosumab works to restore normal phosphate levels in the blood. Specifically, it reduces urinary phosphate excretion and increases the production of active vitamin D (1,25-dihydroxyvitamin D), which in turn enhances intestinal absorption of phosphate and calcium. This targeted mechanism addresses the root cause of XLH, unlike conventional therapies that merely attempt to compensate for the phosphate deficiency.
The introduction of burosumab offered a more physiological approach to managing XLH, leading to sustained improvements in phosphate homeostasis, healing of rickets, and reductions in bone pain in older pediatric and adult patients. Its once-monthly (or once-every-two-weeks for some indications) subcutaneous administration also offers a significant advantage in terms of adherence and convenience compared to the multiple daily doses required by traditional treatments.
The Pivotal BUR-CL207 Trial: Demonstrating Safety and Efficacy in Infants
Clinical data supporting the expanded EC approval for infants are derived from the Phase I/II open-label, multi-centre BUR-CL207 trial. This critical study was specifically designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics of burosumab in a very young and vulnerable patient population: paediatric patients from birth to one year of age. The open-label nature of the trial meant that both researchers and participants knew which treatment was being administered, a common approach in rare disease studies where large placebo-controlled trials may be impractical or ethically challenging.
The trial meticulously assessed various parameters to ensure burosumab’s suitability for infants. Pharmacokinetics (PK) studies determined how the drug is absorbed, distributed, metabolized, and excreted in the infant body, providing crucial information for appropriate dosing. Safety and tolerability were primary endpoints, with researchers closely monitoring for any adverse events. The company reported that the safety profile observed in infants within the BUR-CL207 trial was consistent with the well-established safety profile of burosumab in older paediatric and adult populations. This consistency is reassuring, indicating that the drug’s mechanism of action and side effect profile remain predictable across different age groups, even in developing physiological systems. While specific efficacy endpoints for infants were not detailed in the initial press release, the EC’s approval strongly implies that the trial demonstrated clinically meaningful benefits in normalizing phosphate levels and improving other biomarkers relevant to XLH progression in this age group. The successful completion and positive findings from BUR-CL207 are instrumental, as studies involving neonates and infants are particularly challenging due to ethical considerations, small patient numbers, and the unique physiological characteristics of this age group.
Voices from the Field: Industry and Patient Perspectives
Myriam Hakim, Regional Franchise Head for Kyowa Kirin EMEA, emphasized the profound significance of this approval. "This approval means healthcare professionals can now consider treatment with burosumab from as young as one month of age, creating an opportunity to address the disease earlier than ever before," Hakim stated. "It represents an important step forward for infants living with XLH and the families who care for them." Her comments highlight the transformative potential of early intervention, moving beyond merely managing symptoms to actively preventing the progression of the disease’s most severe manifestations.
The XLH patient community and advocacy groups are expected to welcome this news with immense relief and optimism. For families with infants diagnosed with XLH, the prospect of starting a targeted treatment so early offers a glimmer of hope that their children might avoid the debilitating skeletal deformities, pain, and developmental challenges that have historically plagued individuals with this condition. Early treatment has the potential to significantly improve growth, reduce the severity of rickets, and enhance overall quality of life. Medical professionals specializing in rare bone disorders will likely view this approval as a vital new tool in their therapeutic arsenal, enabling them to implement proactive strategies rather than reactive ones. This shift could lead to better long-term outcomes for patients and a reduction in the need for extensive surgical interventions later in life.
Broader Implications: Transforming Early Intervention and Market Dynamics
Impact on Patients and Families: The most direct and profound impact of this approval will be on infants with XLH and their families. Early initiation of burosumab has the potential to mitigate the irreversible skeletal damage and growth impairment that can occur during the critical developmental window of infancy. By normalizing phosphate levels sooner, it can help promote healthy bone mineralization, improve growth velocity, reduce bone pain, and potentially lessen the burden of surgical procedures in childhood. This translates to improved physical function, better quality of life, and reduced emotional and financial strain on families.
Clinical Practice Changes: The expanded indication will undoubtedly lead to a re-evaluation of diagnostic and treatment protocols for XLH in Europe. Paediatricians, endocrinologists, and geneticists will be encouraged to screen and diagnose XLH earlier in infants presenting with relevant symptoms, knowing that an effective, targeted treatment is available. This could foster greater awareness of XLH among healthcare providers and lead to earlier referrals to specialist centers.
Market Exclusivity and Kyowa Kirin’s Position: This regulatory success also carries significant commercial implications for Kyowa Kirin. The approval further qualifies Crysvita for an additional two years of orphan market exclusivity in the EU for XLH, extending regulatory protection until February 2030. Orphan drug designation is granted to therapies for rare diseases affecting a small number of patients, providing incentives such as market exclusivity to encourage pharmaceutical companies to invest in research and development for conditions that might otherwise be economically unviable. This extended exclusivity solidifies Kyowa Kirin’s strong position in the rare disease market, particularly within the field of metabolic bone disorders, and ensures continued revenue streams for the product. Crysvita has been a cornerstone of Kyowa Kirin’s portfolio, and expanding its approved uses strengthens its market leadership.
Reimbursement Landscape: While the EC approval grants marketing authorization, the actual availability and affordability of burosumab for infants will depend on national reimbursement decisions across individual EU and EEA member states. Burosumab is already reimbursed in various European countries, including France, Germany, Italy, Spain, and the UK, for both paediatric and adult XLH populations. Given the established clinical benefits and the orphan drug status, it is highly anticipated that national health systems will move to provide reimbursement for this critical infant indication, recognizing the long-term health and economic benefits of early intervention. However, the process of securing reimbursement can be lengthy and complex in each country.
Future Outlook and Research: This approval opens avenues for further research into the long-term outcomes of initiating burosumab treatment in infancy. Studies will likely focus on assessing the full impact on adult height, skeletal health, dental issues, and overall quality of life in individuals treated from a very young age. It also reinforces the scientific principle that early, targeted intervention in genetic disorders can significantly alter disease progression and improve patient prognosis.
In conclusion, the European Commission’s expanded approval of Crysvita for infants with XLH marks a momentous occasion for the rare disease community. It embodies the success of dedicated research and development, robust clinical trials, and a responsive regulatory environment focused on addressing unmet medical needs. For the youngest patients afflicted by X-linked hypophosphataemia in Europe, this decision offers a profound opportunity for a healthier future, less burdened by the severe consequences of this challenging condition.
